Clinical-stage company Pharvaris N.V. (PHVS) announced Monday the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study.
Shares of Pharvaris (NASDAQ:PHVS – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $26.10, but opened at $25.51. Pharvaris shares last traded at $25.95, with a volume of 1,906 shares trading hands. Analysts Set New Price Targets Several brokerages have recently weighed in on PHVS. Bank […]
Pharvaris (NASDAQ:PHVS – Free Report) had its price target decreased by Morgan Stanley from $34.00 to $32.00 in a report published on Tuesday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock. Separately, Wedbush reduced their price objective on shares of Pharvaris from $27.00 to $24.00 and set an outperform rating for […]
Pharvaris (NASDAQ:PHVS – Get Free Report) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 12,500 shares, a decline of 20.9% from the September 30th total of 15,800 shares. Based on an average daily volume of 47,500 shares, the short-interest […]
Pharvaris (NASDAQ:PHVS – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 12,500 shares, a decline of 20.9% from the September 30th total of 15,800 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily […]